Claims for Patent: 7,718,425

Summary for Patent: 7,718,425

Title:	Use of a B-cell-depleting antibody for treatment of polyoma virus infections
Abstract:	The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection.
Inventor(s):	Reinke; Petra (Berlin, DE), Volk; Hans-Dieter (Berlin, DE), Hammer; Markus (Berlin, DE), Babel; Nina (Berlin, DE), Bold; Gana (Berlin, DE)
Assignee:	Charite-Universit{umlaut over ( )}atsmedizin Berlin (Berlin, DE)
Application Number:	12/299,142
Patent Claims:	1. A method of treatment of a polyoma virus infection using a-B-cell depleting antibody, wherein said polyoma virus infection is in a patient having a nephropathy, preferably a polyoma virus associated nephropathy, comprising administering said B-cell depleting antibody to said patient in a dose of about 1 mg to 1 g. 2. The method according to claim 1, wherein said nephropathy is selected from the group comprising glomerulonephritis, interstitial nephiritis, and pyelonephritis. 3. The method according to claim 1, wherein said polyoma virus infection is in a patient having a hemorrhagic cystitis, preferably a polyoma virus associated hemorrhagic cystitis. 4. The method according to claim 1, wherein said polyoma virus infection is in a patient having received a transplantation or being supposed to receive transplantation. 5. The method according to claim 4, wherein said transplantation is a solid organ transplantation or a bone marrow transplantation or a stem-cell transplantation. 6. The method according to claim 4, wherein said transplantation is a solid organ transplantation, preferably a renal transplantation. 7. The method according to claim 4, wherein said transplantation is a bone marrow transplantation or a stem cell transplantation. 8. The method according to claim 1, wherein said polyoma virus infection is in a patient having progressive multifocal leukoencephalopathy. 9. The method according to claim 8, wherein said progressive multifocal leucoencephalopathy is in a patient having a deficient immune system. 10. The method according to claim 9, wherein said deficient immune system is an immune system suppressed by medication or is an immune system deficient because of an infection by human immune deficiency virus (HIV) or because of an affection by systemic lupus erythematosus. 11. The method according to claim 1, wherein said B-cell depleting antibody is an anti-CD20-antibody. 12. The method according to claim 11, wherein said B-cell depleting antibody is selected from the group comprising rituximab and antibodies directed against B-cell surface molecules, more preferably antibodies directed against B-cell specific surface molecules, such as CD19, CD20, CD22, CD72, CD79a, CD79b. 13. The method according to claim 1, wherein said B-cell depleting antibody is administered in a dose of 100 mg to 800 mg, more preferably 250 mg to 750 mg, most preferably 300 mg to 500 mg. 14. The method according to claim 13, wherein said B-cell depleting antibody is administered in one dose every 2-20 days, preferably one dose every 7-14 days. 15. The method according to claim 13, wherein said B-cell depleting antibody is administered in one dose every 1-3 days. 16. The method according to claim 13, wherein said B-cell depleting antibody is administered in 1-20 doses in total, preferably in 1-10 doses, more preferably 1-8 doses, and most preferably 1-4 doses in total. 17. The method according to claim 13, wherein said administration is systemical, preferably via injection or infusion, more preferably an intravenous injection or infusion. 18. The method according to claim 13, wherein said administration results in a reduction of virus titre by 1-4 log DNA copies/ml serum or urine, as measured by PCR, preferably real-time PCR. 19. The method according to claim 5, wherein said B-cell depleting antibody is administered to a patient in need thereof, and said administration results in a prevention of a deterioration of the function of the transplanted solid organ or bone marrow or stem cells, or in the prevention of a rejection thereof after transplantation. 20. The method according to claim 19, wherein said patient is a non-responder or a relapser after a previous treatment by cidofovir and/or hyperimmune globulins. 21. The method according to claim 19, wherein said B-cell depleting antibody is administered prior to or after said solid organ transplantation or said bone marrow transplantation or said stem cell transplantation. 22. The method according to claim 1, wherein said B-cell depleting antibody is administered in combination with other medication, preferably in combination with antiviral medication, such as cidofovir or hyperimmune globulins, and/or with anti-inflammatory agents, such as steroids or immune-suppressants.

Details for Patent 7,718,425

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-05-02
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-05-02
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2026-05-02